Plasmodium falciparum polymorphisms associated with ex vivo drug susceptibility and clinical effectiveness of artemisinin-based combination therapies in benin

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 1-10

  Dahlström, Sabina ^a   Aubouy, Agnès ^b,c   Maïga Ascofaré, Oumou ^a   Faucher, Jean François ^b,c,d   Wakpo, Abel ^e   Ezinmègnon, Sèm ^e   Massougbodji, Achille ^e   Houzé, Pascal ^f   Kendjo, Eric ^g,h   Deloron, Philippe ^b,c   Le Bras, Jacques ^a,b,c,g   Houzé, Sandrine ^b,c,g  

^a Hosp University Bichat C Bernard   (France)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^e CERPAGE Laboratory   (Benin)

^f SAINT LOUIS HOSPITAL   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ARTEMETHER PLUS BENFLUMETOL; BENFLUMETOL; DEETHYLAMODIAQUINE; DIHYDROARTEMISININ; LACTATE DEHYDROGENASE; MEFLOQUINE; PYRIMETHAMINE; PYRIMETHAMINE PLUS SULFADOXINE; QUININE; YTTRIUM 86;

ALLELE; ARTICLE; BENIN; CLINICAL EFFECTIVENESS; CLONING; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FOLLOW UP; GENETIC LINKAGE; GROWTH INHIBITION; HUMAN; IC 50; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALARIA; MALARIA FALCIPARUM; OUTCOME ASSESSMENT; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RECURRENT INFECTION; REINFECTION;

AMODIAQUINE; ANTIMALARIALS; ARTEMISININS; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MEFLOQUINE; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PLASMODIUM FALCIPARUM; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTOZOAN PROTEINS; PYRIMETHAMINE; QUININE; SULFADOXINE;

EID: 84891545646     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01790-12     Document Type: Article

References (58)

1. WHO. 2011. World malaria report. WHO, Geneva, Switzerland. http://www.who.int/malaria/world-malaria-report-2011/en/.
2. Snow RW, Trape JF, Marsh K. 2001. The past, present and future of childhood malaria mortality in Africa. Trends Parasitol. 17:593-597. http://dx.doi.org/10.1016/S1471-4922(01)02031-1.
3. Trape JF, Pison G, Preziosi MP, Enel C, Desgrees du Lou A, Delaunay V, Samb B, Lagarde E, Molez JF, Simondon F. 1998. Impact of chloroquine resistance on malaria mortality. C. R. Acad. Sci. III 321:689-697. http://dx.doi.org/10. 1016/S0764-4469(98)80009-7.
4. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361:455-467. http://dx.doi.org/10.1056/NEJMoa0808859.
5. Noedl H, Se Y, Sriwichai S, Schaecher K, Teja-Isavadharm P, Smith B, Rutvisuttinunt W, Bethell D, Surasri S, Fukuda MM, Socheat D, Chan Thap L. 2010. Artemisinin resistance in Cambodia: A clinical trial designed to address an emerging problem in Southeast Asia. Clin. Infect. Dis. 51:e82- e89. http://dx.doi.org/10.1086/657120.
6. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, ler Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NP, White NJ, Anderson TJ, Nosten F. 2012. Emergence of artemisinin-resistant malaria on the western border of Thailand: A longitudinal study. Lancet 379: 1960-1966. http://dx.doi.org/10.1016/S0140-6736(12)60484-X.
7. WHO. 2010. Global report on antimalarial efficacy and drug resistance: 2000-2010. WHO, Geneva, Switzerland. http://www.who.int/malaria/publications/ atoz/9789241500470/en/index.html.
8. O'Brien C, Henrich PP, Passi N, Fidock DA. 2011. Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Curr. Opin. Infect. Dis. 24:570-577. http://dx.doi.org/10.1097/QCO. 0b013e32834cd3ed.
9. Thanh NV, Toan TQ, Cowman AF, Casey GJ, Phuc BQ, Tien NT, Hung NM, Biggs BA. 2010. Monitoring for Plasmodium falciparum drug resistance to artemisinin and artesunate in Binh Phuoc Province, Vietnam: 1998-2009. Malar. J. 9:181. http://dx.doi.org/10.1186/1475-2875-9-181.
10. Cheeseman IH, Miller BA, Nair S, Nkhoma S, Tan A, Tan JC, Al Saai S, Phyo AP, Moo CL, Lwin KM, McGready R, Ashley E, Imwong M, Stepniewska K, Yi P, Dondorp AM, Mayxay M, Newton PN, White NJ, Nosten F, Ferdig MT, Anderson TJ. 2012. A major genome region underlying artemisinin resistance in malaria. Science 336:79-82. http://dx.doi.org/10.1126/science.1215966.
11. Dahlström S, Ferreira PE, Veiga MI, Sedighi N, Wiklund L, Martensson A, Farnert A, Sisowath C, Osorio L, Darban H, Andersson B, Kaneko A, Conseil G, Bjorkman A, Gil JP. 2009. Plasmodium falciparum multidrug resistance protein 1 and artemisinin-based combination therapy in Africa. J. Infect. Dis. 200:1456-1464. http://dx.doi.org/10.1086/606009.
12. Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ, Dorsey G. 2006. Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob. Agents Chemother. 50:1893-1895. http://dx.doi.org/10.1128/AAC.50.5. 1893-1895.2006.
13. Holmgren G, Hamrin J, Svard J, Martensson A, Gil JP, Bjorkman A. 2007. Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa. Infect. Genet. Evol. 7:562-569. http://dx.doi.org/10.1016/j.meegid.2007.03.005.
14. Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJ, Mutabingwa TK, Sutherland CJ, Hallett RL. 2007. Amodiaquine and artemetherlumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob. Agents Chemother. 51:991-997. http://dx.doi.org/10.1128/AAC.00875-06.
15. Nsobya SL, Dokomajilar C, Joloba M, Dorsey G, Rosenthal PJ. 2007. Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda. Antimicrob. Agents Chemother. 51:3023-3025. http://dx.doi.org/10.1128/AAC.00012-07.
16. Sisowath C, Ferreira PE, Bustamante LY, Dahlstrom S, Martensson A, Bjorkman A, Krishna S, Gil JP. 2007. The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop. Med. Int. Health 12:736-742. http://dx.doi.org/10.1111/j.1365-3156.2007.01843.x.
17. Sisowath C, Petersen I, Veiga MI, Martensson A, Premji Z, Bjorkman A, Fidock DA, Gil JP. 2009. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J. Infect. Dis. 199:750-757. http://dx.doi.org/10.1086/596738.
18. Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Bjorkman A, Gil JP. 2005. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J. Infect. Dis. 191:1014-1017. http://dx.doi.org/10.1086/427997.
19. Mwai L, Kiara SM, Abdirahman A, Pole L, Rippert A, Diriye A, Bull P, Marsh K, Borrmann S, Nzila A. 2009. In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob. Agents Chemother. 53:5069-5073. http://dx.doi.org/10.1128/AAC.00638-09.
20. Nsobya SL, Kiggundu M, Nanyunja S, Joloba M, Greenhouse B, Rosenthal PJ. 2010. In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob. Agents Chemother. 54:1200-1206. http://dx.doi.org/10.1128/AAC.01412-09.
21. Djimdé AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, Dama S, Ouologuem D, Dicko A, Doumbo OK. 2008. Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Am. J. Trop. Med. Hyg. 78:455-461.
22. Happi CT, Gbotosho GO, Folarin OA, Sowunmi A, Hudson T, O'Neil M, Milhous W, Wirth DF, Oduola AM. 2009. Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria. Antimicrob. Agents Chemother. 53:888-895.http://dx.doi.org/10.1128/AAC. 00968-08.
23. Somé AF, Sere YY, Dokomajilar C, Zongo I, Rouamba N, Greenhouse B, Ouedraogo JB, Rosenthal PJ. 2010. Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemetherlumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin- piperaquine in Burkina Faso. Antimicrob. Agents Chemother. 54:1949-1954. http://dx.doi.org/10. 1128/AAC.01413-09.
24. Dippmann AK, Bienzle U, Harms G, Mockenhaupt FP. 2008. pfmdr1 mutations in imported African Plasmodium falciparum isolates. Trans. R. Soc. Trop. Med. Hyg. 102:1148-1150. http://dx.doi.org/10.1016/j.trstmh.2008.04.001.
25. Faucher JF, Aubouy A, Adeothy A, Cottrell G, Doritchamou J, Gourmel B, Houze P, Kossou H, Amedome H, Massougbodji A, Cot M, Deloron P. 2009. Comparison of sulfadoxine-pyrimethamine, unsupervised artemether- lumefantrine, and unsupervised artesunate-amodiaquine fixeddose formulation for uncomplicated Plasmodium falciparum malaria in Benin: A randomized effectiveness noninferiority trial. J. Infect. Dis. 200: 57-65. http://dx.doi.org/10.1086/ 599378.
26. Le Bras J, Deloron P. 1983. In vitro study of drug sensitivity of Plasmodium falciparum: evaluation of a new semi-micro test. Am. J. Trop. Med. Hyg. 32:447-451.
27. Kaddouri H, Nakache S, Houze S, Mentre F, Le Bras J. 2006. Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from Africa by using a Plasmodium lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration. Antimicrob. Agents Chemother. 50:3343-3349. http://dx.doi.org/10.1128/AAC.00367-06.
28. Le Nagard H, Vincent C, Mentre F, Le Bras J. 2011. Online analysis of in vitro resistance to antimalarial drugs through nonlinear regression. Comput. Methods Programs Biomed. 104:10-18. http://dx.doi.org/10.1016/j.cmpb.2010.08. 003.
29. Dahlström S, Veiga MI, Ferreira P, Martensson A, Kaneko A, Andersson B, Bjorkman A, Gil JP. 2008. Diversity of the sarco/endoplasmic reticulum Ca(2+)-ATPase orthologue of Plasmodium falciparum (PfATP6). Infect. Genet. Evol. 8:340-345. http://dx.doi.org/10.1016/j.meegid.2008.02.002.
30. Dahlström S, Veiga MI, Martensson A, Bjorkman A, Gil JP. 2009. Polymorphism in PfMRP1 (Plasmodium falciparum multidrug resistance protein 1) amino acid 1466 associated with resistance to sulfadoxinepyrimethamine treatment. Antimicrob. Agents Chemother. 53:2553-2556. http://dx.doi.org/10. 1128/AAC.00091-09.
31. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Coulibaly D, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV. 2001. A molecular marker for chloroquine-resistant falciparum malaria. N. Engl. J. Med. 344:257-263. http://dx.doi.org/10.1056/NEJM200101253440403.
32. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC. 2000. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol. Biochem. Parasitol. 108:13-23. http://dx.doi.org/10.1016/ S0166-6851(00)00201-2.
33. Maïga O, Djimde AA, Hubert V, Renard E, Aubouy A, Kironde F, Nsimba B, Koram K, Doumbo OK, Le Bras J, Clain J. 2007. A shared Asian origin of the triple-mutant dhfr allele in Plasmodium falciparum from sites across Africa. J. Infect. Dis. 196:165-172. http://dx.doi.org/10.1086/518512.
34. Duraisingh MT, Curtis J, Warhurst DC. 1998. Plasmodium falciparum: Detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Exp. Parasitol. 89:1-8. http://dx.doi.org/10.1006/expr.1998.4274.
35. Dahlstrom S. 2009. Role of PfATP6 and pfMRP1 in Plasmodium falciparum resistance to antimalarial drugs. Ph.D. thesis. Karolinska Institutet, Stockholm, Sweden.
36. Aubouy A, Fievet N, Bertin G, Sagbo JC, Kossou H, Kinde-Gazard D, Kiniffo R, Massougbodji A, Deloron P. 2007. Dramatically decreased therapeutic efficacy of chloroquine and sulfadoxine-pyrimethamine, but not mefloquine, in southern Benin. Trop. Med. Int. Health 12:886-894. http://dx.doi.org/10.1111/j.1365-3156. 2007.01859.x.
37. Basco LK, Le Bras J, Rhoades Z, Wilson CM. 1995. Analysis of pfmdr1 and drug susceptibility in fresh isolates of Plasmodium falciparum from subsaharan Africa. Mol. Biochem. Parasitol. 74:157-166. http://dx.doi.org/10.1016/0166- 6851(95)02492-1.
38. Gesase S, Gosling RD, Hashim R, Ord R, Naidoo I, Madebe R, Mosha JF, Joho A, Mandia V, Mrema H, Mapunda E, Savael Z, Lemnge M, Mosha FW, Greenwood B, Roper C, Chandramohan D. 2009. High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at codon 581. PLoS One 4:e4569. http://dx.doi.org/10.1371/ journal.pone.0004569.
39. Bertin G, Briand V, Bonaventure D, Carrieu A, Massougbodji A, Cot M, Deloron P. 2011. Molecular markers of resistance to sulphadoxinepyrimethamine during intermittent preventive treatment of pregnant women in Benin. Malar. J. 10:196. http://dx.doi.org/10.1186/1475-2875-10-196.
40. Basco LK, Le Bras J. 1993. In vitro activity of monodesethylamodiaquine and amopyroquine against African isolates and clones of Plasmodium falciparum. Am. J. Trop. Med. Hyg. 48:120-125.
41. Childs GE, Boudreau EF, Milhous WK, Wimonwattratee T, Pooyindee N, Pang L, Davidson DE, Jr. 1989. A comparison of the in vitro activities of amodiaquine and desethylamodiaquine against isolates of Plasmodium falciparum. Am. J. Trop. Med. Hyg. 40:7-11
42. Skinner TS, Manning LS, Johnston WA, Davis TM. 1996. In vitro stage-specific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. Int. J. Parasitol. 26:519-525. http://dx.doi.org/10.1016/0020-7519(96) 89380-5.
43. Witkowski B, Khim N, Chim P, Kim S, Ke S, Kloeung N, Chy S, Duong S, Leang R, Ringwald P, Dondorp AM, Tripura R, Benoit-Vical F, Berry A, Gorgette O, Ariey F, Barale JC, Mercereau-Puijalon O, Menard D. 3 December 2012. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob. Agents Chemother. http://dx.doi.org/10.1128/AAC.01868-12.
44. Basco LK, Bickii J, Ringwald P. 1998. In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Antimicrob. Agents Chemother. 42:2347-2351.
45. Pradines B, Hovette P, Fusai T, Atanda HL, Baret E, Cheval P, Mosnier J, Callec A, Cren J, Amalvict R, Gardair JP, Rogier C. 2006. Prevalence of in vitro resistance to eleven standard or new antimalarial drugs among Plasmodium falciparum isolates from Pointe-Noire, Republic of the Congo. J. Clin. Microbiol. 44:2404-2408. http://dx.doi.org/10.1128/JCM.00623-06.
46. Duraisingh MT, Roper C, Walliker D, Warhurst DC. 2000. Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum. Mol. Microbiol. 36:955-961. http://dx.doi.org/10.1046/j.1365-2958.2000.01914.x.
47. Gadalla NB, Adam I, Elzaki SE, Bashir S, Mukhtar I, Oguike M, Gadalla A, Mansour F, Warhurst D, El-Sayed BB, Sutherland CJ. 2011. Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether- lumefantrine. Antimicrob. Agents Chemother. 55:5408-5411. http://dx.doi.org/10.1128/AAC.05102-11.
48. Baliraine FN, Rosenthal PJ. 2011. Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemetherlumefantrine in Uganda. J. Infect. Dis. 204:1120-1124. http://dx.doi.org/10.1093/infdis/ jir486.
49. Stepniewska K, White NJ. 2008. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob. Agents Chemother. 52:1589-1596. http://dx.doi.org/10.1128/AAC.00903-07.
50. White N. 1999. Antimalarial drug resistance and combination chemotherapy. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354:739-749. http://dx.doi.org/10. 1098/rstb.1999.0426.
51. Malmberg M, Ferreira PE, Tarning J, Ursing J, Ngasala B, Björkman A, Ma°rtensson A, Gil JP. 5 December 2012. Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms. J. Infect. Dis. http://dx.doi.org/10. 1093/infdis/jis747.
52. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. 2000. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 403:906-909. http://dx.doi.org/10.1038/35002615.
53. Okombo J, Ohuma E, Picot S, Nzila A. 2011. Update on genetic markers of quinine resistance in Plasmodium falciparum. Mol. Biochem. Parasitol. 177:77-82. http://dx.doi.org/10.1016/j.molbiopara.2011.01.012.
54. Ferdig MT, Cooper RA, Mu J, Deng B, Joy DA, Su XZ, Wellems TE. 2004. Dissecting the loci of low-level quinine resistance in malaria parasites. Mol. Microbiol. 52:985-997. http://dx.doi.org/10.1111/j.1365-2958.2004.04035.x.
55. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA. 2001. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597- 607. http://dx.doi.org/10.1097/00008571-200110000-00006.
56. Li XQ, Bjorkman A, Andersson TB, Ridderstrom M, Masimirembwa CM. 2002. Amodiaquine clearance and its metabolism to Ndesethylamodiaquine is mediated by CYP2C8: A new high affinity and turnover enzyme-specific probe substrate. J. Pharmacol. Exp. Ther. 300: 399-407. http://dx.doi.org/10.1124/jpet.300.2.399.
57. Aubouy A, Mayombo J, Keundjian A, Bakary M, Le Bras J, Deloron P. 2004. Short report: lack of prediction of amodiaquine efficacy in treating Plasmodium falciparum malaria by in vitro tests. Am. J. Trop. Med. Hyg. 71:294-296.
58. Smith DL, Klein EY, McKenzie FE, Laxminarayan R. 2010. Prospective strategies to delay the evolution of anti-malarial drug resistance: Weighing the uncertainty. Malar. J. 9:217. http://dx.doi.org/10.1186/1475-2875-9-217.